The therapeutic and prophylactic potential of quercetin against COVID-19: An outlook on the clinical studies, inventive compositions, and patent literature
Quercetin is a phenolic flavonol compound with established antioxidant, anti-inflammatory,
and immuno-stimulant properties. Recent studies demonstrate the potential of quercetin …
and immuno-stimulant properties. Recent studies demonstrate the potential of quercetin …
Nigella sativa L. and COVID-19: A Glance at The Anti-COVID-19 Chemical Constituents, Clinical Trials, Inventions, and Patent Literature
COVID-19 has had an impact on human quality of life and economics. Scientists have been
identifying remedies for its prevention and treatment from all possible sources, including …
identifying remedies for its prevention and treatment from all possible sources, including …
DG-Affinity: predicting antigen–antibody affinity with language models from sequences
Background Antibody-mediated immune responses play a crucial role in the immune
defense of human body. The evolution of bioengineering has led the progress of antibody …
defense of human body. The evolution of bioengineering has led the progress of antibody …
Keeping up with the COVID's—Could siRNA‐based antivirals be a part of the answer?
Abstract Coronavirus disease 2019 (COVID‐19) is a highly contagious viral disease caused
by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). This deadly infection …
by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). This deadly infection …
Effects of casirivimab/imdevimab monoclonal antibody treatment among vaccinated patients infected by SARS-CoV-2 delta variant
G Cicchitto, L Cardillo, C de Martinis, P Sabatini… - Viruses, 2022 - mdpi.com
There is a growing interest in using monoclonal antibodies (mAbs) in the early stages of
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection to prevent …
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection to prevent …
Therapeutic development targeting host heparan sulfate proteoglycan in SARS-CoV-2 infection
The global pandemic caused by the severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) has led to an urgent need for effective therapeutic options. SARS-CoV-2 is a …
(SARS-CoV-2) has led to an urgent need for effective therapeutic options. SARS-CoV-2 is a …
Therapeutic Potential of Neutralizing Monoclonal Antibodies (nMAbs) against SARS-CoV-2 Omicron Variant
P Parua, S Ghosh, K Jana, A Seth… - Current …, 2024 - benthamdirect.com
Background The COVID-19 pandemic has spurred significant endeavors to devise
treatments to combat SARS-CoV-2. A limited array of small-molecule antiviral drugs …
treatments to combat SARS-CoV-2. A limited array of small-molecule antiviral drugs …
What, where, when and how of COVID-19 patents landscape: a Bibliometrics review
K Liu, X Zhang, Y Hu, W Chen, X Kong, P Yao… - Frontiers in …, 2022 - frontiersin.org
Two years after COVID-19 came into being, many technologies have been developed to
bring highly promising bedside methods to help fight this epidemic disease. However, owing …
bring highly promising bedside methods to help fight this epidemic disease. However, owing …
Antibody Therapy for COVID-19: Categories, Pros, and Cons
H Zare Marzouni, M Rahbar, N Seddighi… - Viral …, 2022 - liebertpub.com
COVID-19 is a life-threatening respiratory disease triggered by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2). It has been considered a pandemic viral infection …
syndrome coronavirus 2 (SARS-CoV-2). It has been considered a pandemic viral infection …
Monoclonal antibody targeting a novel linear epitope on nucleoprotein confers pan-reactivity to influenza A virus
M Gu, J Jiao, S Liu, W Zhao, Z Ge, K Cai, L Xu… - Applied Microbiology …, 2023 - Springer
Nucleoprotein (NP) functions crucially in the replicative cycle of influenza A virus (IAV) via
forming the ribonucleoprotein complex together with PB2, PB1, and PA proteins. As its high …
forming the ribonucleoprotein complex together with PB2, PB1, and PA proteins. As its high …